Myriad Genetics, Inc.
MYD.DE
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.15B
Close$
Share Statistics
| Market cap | $2.15 Billion |
|---|---|
| Enterprise Value | $2.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.41 |
| Beta | 1.96 |
| Outstanding Shares | 90,724,343 |
Return
| Return on Equity | -37.05% |
|---|---|
| Return on Assets | -17.62% |
| Return on Invested Capital | -18.85% |
Valuation & Multiples
| P/E Ratio | -3.61 |
|---|---|
| PEG | 4.15 |
| Price to Sales | 3.34 |
| Price to Book Ratio | 8.91 |
| Enterprise Value to Revenue | 2.79 |
| Enterprise Value to EBIT | -23.48 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...